Simplified medical abortion screening: a demonstration project
- PMID: 29170088
- DOI: 10.1016/j.contraception.2017.11.005
Simplified medical abortion screening: a demonstration project
Abstract
Objectives: The objectives were to evaluate the safety and acceptability of outpatient medical abortion in selected women without a pretreatment ultrasound or pelvic examination.
Study design: We conducted a prospective case-series study to estimate the incidence of serious adverse events (death, life-threatening event, hospitalization, transfusion or any other medical problem that we judged to be significant), surgical completion of the abortion and satisfaction in women provided with medical abortion without a pretreatment ultrasound or pelvic examination. We enrolled 406 women requesting medical abortion in Moldova, Mexico and the United States. To be eligible, a woman must have been certain that her last menstrual period started within the prior 56days, have had regular menses before the pregnancy, not have used hormonal contraceptives in the prior 2months (in the United States and Mexico) or 3months (in Moldova), have no risk factors for or symptoms of ectopic pregnancy, and not have had an ultrasound or pelvic exam in this pregnancy. One site also excluded women with uterine enlargement on abdominal palpation. Each participant received mifepristone (200mg orally) and misoprostol (400 mcg sublingually in Moldova; 800 mcg buccally at all other sites) and was followed until complete abortion, defined as requiring no further treatment.
Results: Of the 365 (90%) participants who provided sufficient follow-up information for analysis, 347 (95%) had complete abortion without additional treatment, 5 (1%) had surgical aspiration, and 10 (3%) had extra misoprostol. Three participants (1%) had serious adverse events; these included two hospital admissions for heavy bleeding managed with aspiration and one diagnosis of persistent gestational sac 19days after enrollment. Most (317, 90%) participants were pleased with omitting the pretreatment ultrasound and pelvic exam.
Conclusions: In this study, medical abortion without screening ultrasound or pelvic exam resulted in no serious adverse events that were likely to have been prevented by those tests and was highly acceptable.
Implications: Screening for medical abortion without exam or ultrasound shows promise as a means for increasing access to this service. More research is needed to develop screening criteria that are more inclusive and simpler for clinical use.
Trial registration: ClinicalTrials.gov NCT02381223.
Keywords: Ectopic pregnancy; Last menstrual period; Medical abortion; Ultrasound.
Copyright © 2017. Published by Elsevier Inc.
Similar articles
-
Mifepristone and misoprostol for early abortion when no gestational sac is present.Contraception. 2001 May;63(5):251-4. doi: 10.1016/s0010-7824(01)00200-1. Contraception. 2001. PMID: 11448464 Clinical Trial.
-
Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.Contraception. 1999 Jan;59(1):1-6. doi: 10.1016/s0010-7824(98)00150-4. Contraception. 1999. PMID: 10342079 Clinical Trial.
-
Randomised controlled trial comparing the efficacy of same-day administration of mifepristone and misoprostol for termination of pregnancy with the standard 36 to 48 hour protocol.BJOG. 2007 Feb;114(2):207-15. doi: 10.1111/j.1471-0528.2006.01179.x. BJOG. 2007. PMID: 17305893 Clinical Trial.
-
Expanding medical abortion: can medical abortion be effectively provided without the routine use of ultrasound?Contraception. 2011 Mar;83(3):194-201. doi: 10.1016/j.contraception.2010.07.023. Epub 2010 Sep 17. Contraception. 2011. PMID: 21310279 Review.
-
Second trimester medical abortion with mifepristone-misoprostol and misoprostol alone: a review of methods and management.Reprod Health Matters. 2008 May;16(31 Suppl):162-72. doi: 10.1016/S0968-8080(08)31371-8. Reprod Health Matters. 2008. PMID: 18772097 Review.
Cited by
-
Gestational dating using last menstrual period and bimanual exam for medication abortion in pharmacies and health centers in Nepal.Contraception. 2018 Oct;98(4):296-300. doi: 10.1016/j.contraception.2018.06.004. Epub 2018 Jun 21. Contraception. 2018. PMID: 29936150 Free PMC article.
-
Safety and Efficacy of Telehealth Medication Abortions in the US During the COVID-19 Pandemic.JAMA Netw Open. 2021 Aug 2;4(8):e2122320. doi: 10.1001/jamanetworkopen.2021.22320. JAMA Netw Open. 2021. PMID: 34427682 Free PMC article.
-
Medication to Manage Abortion and Miscarriage.J Gen Intern Med. 2020 Aug;35(8):2398-2405. doi: 10.1007/s11606-020-05836-9. Epub 2020 May 14. J Gen Intern Med. 2020. PMID: 32410127 Free PMC article. Review.
-
Adoption of no-test and telehealth medication abortion care among independent abortion providers in response to COVID-19.Contracept X. 2020 Nov 21;2:100049. doi: 10.1016/j.conx.2020.100049. eCollection 2020. Contracept X. 2020. PMID: 33305255 Free PMC article.
-
Expansion of a direct-to-patient telemedicine abortion service in the United States and experience during the COVID-19 pandemic.Contraception. 2021 Jul;104(1):43-48. doi: 10.1016/j.contraception.2021.03.019. Epub 2021 Mar 27. Contraception. 2021. PMID: 33781762 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical